A precise understanding of how the enzyme topoisomerase II cuts DNA could lead to better anti-cancer therapies.
Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.
A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.
Wellington Pham, PhD, and colleagues in Japan, have developed a nanobeacon imaging agent to aid the early detection of colorectal cancer during colonoscopy.
The protein STK17A (serine threonine kinase 17A) appears to play roles in various cancer types. Researchers have found that cells without STK17A become less connected and more invasive.
Vanderbilt researchers have mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.
Vanderbilt investigators have discovered a new DNA repair pathway that guards against genomic mutations. Their findings were published recently in the journal Cell.
Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team for calculating drug synergy.
Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
Changes in enzymes involved in lysophospholipid signaling can activate a pathway implicated in development of cancer, a recent study suggests.